Business Description
Jagsonpal Pharmaceuticals Ltd
ISIN : INE048B01027
Compare
Compare
Traded in other countries / regions
JAGSNPHARM.India IPO Date
2000-03-01Description
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company has a single reporting segment namely, the Pharmaceutical segment, and derives its revenue from the same. Its brands comprise Lycored, Maintane, Metadec, Metabol, Doxypal DR, and others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.01 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.27 | |||||
| Interest Coverage | 38.05 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 15.09 | |||||
| Beneish M-Score | -2.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.3 | |||||
| 3-Year EBITDA Growth Rate | 49.2 | |||||
| 3-Year EPS without NRI Growth Rate | 55.6 | |||||
| 3-Year FCF Growth Rate | 66.5 | |||||
| 3-Year Book Growth Rate | 12.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.83 | |||||
| 9-Day RSI | 63.19 | |||||
| 14-Day RSI | 60.56 | |||||
| 6-1 Month Momentum % | -29.37 | |||||
| 12-1 Month Momentum % | -17.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.34 | |||||
| Quick Ratio | 5.64 | |||||
| Cash Ratio | 3.89 | |||||
| Days Inventory | 85.56 | |||||
| Days Sales Outstanding | 38.48 | |||||
| Days Payable | 60.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.5 | |||||
| Dividend Payout Ratio | 0.53 | |||||
| Forward Dividend Yield % | 1.5 | |||||
| 5-Year Yield-on-Cost % | 1.5 | |||||
| Shareholder Yield % | 1.39 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.2 | |||||
| Operating Margin % | 11.35 | |||||
| Net Margin % | 11.11 | |||||
| FCF Margin % | 21 | |||||
| ROE % | 15.77 | |||||
| ROA % | 12.91 | |||||
| ROIC % | 24.43 | |||||
| ROC (Joel Greenblatt) % | 63 | |||||
| ROCE % | 20.3 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.42 | |||||
| PE Ratio without NRI | 32.8 | |||||
| Shiller PE Ratio | 70.85 | |||||
| Price-to-Owner-Earnings | 22.81 | |||||
| PS Ratio | 3.72 | |||||
| PB Ratio | 4.81 | |||||
| Price-to-Tangible-Book | 5.04 | |||||
| Price-to-Free-Cash-Flow | 17.57 | |||||
| Price-to-Operating-Cash-Flow | 17.45 | |||||
| EV-to-EBIT | 22.81 | |||||
| EV-to-EBITDA | 21.68 | |||||
| EV-to-Revenue | 3.44 | |||||
| EV-to-FCF | 15.96 | |||||
| Price-to-Projected-FCF | 2.83 | |||||
| Price-to-Median-PS-Value | 5.79 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.38 | |||||
| Price-to-Graham-Number | 2.58 | |||||
| Price-to-Net-Current-Asset-Value | 5.99 | |||||
| Price-to-Net-Cash | 11.89 | |||||
| Earnings Yield (Greenblatt) % | 4.38 | |||||
| FCF Yield % | 5.37 | |||||
| Forward Rate of Return (Yacktman) % | 3.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jagsonpal Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 2,206.67 | ||
| EPS (TTM) (₹) | 9.3 | ||
| Beta | 0.08 | ||
| Volatility % | 43.1 | ||
| 14-Day RSI | 60.56 | ||
| 14-Day ATR (₹) | 13.310316 | ||
| 20-Day SMA (₹) | 303.28 | ||
| 12-1 Month Momentum % | -17.93 | ||
| 52-Week Range (₹) | 273.6 - 514.85 | ||
| Shares Outstanding (Mil) | 26.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jagsonpal Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jagsonpal Pharmaceuticals Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jagsonpal Pharmaceuticals Ltd Frequently Asked Questions
What is Jagsonpal Pharmaceuticals Ltd(NSE:JAGSNPHARM)'s stock price today?
The current price of NSE:JAGSNPHARM is ₹325.60. The 52 week high of NSE:JAGSNPHARM is ₹514.85 and 52 week low is ₹273.60.
When is next earnings date of Jagsonpal Pharmaceuticals Ltd(NSE:JAGSNPHARM)?
The next earnings date of Jagsonpal Pharmaceuticals Ltd(NSE:JAGSNPHARM) is .
Does Jagsonpal Pharmaceuticals Ltd(NSE:JAGSNPHARM) pay dividends? If so, how much?
The Dividend Yield %  of Jagsonpal Pharmaceuticals Ltd(NSE:JAGSNPHARM) is 1.5% (As of Today), Highest Dividend Payout Ratio of Jagsonpal Pharmaceuticals Ltd(NSE:JAGSNPHARM) was 1.11. The lowest was 0.04. And the median was 0.14. The  Forward Dividend Yield % of Jagsonpal Pharmaceuticals Ltd(NSE:JAGSNPHARM) is 1.5%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers